1. Almaani, S., Meara, A. & Rovin, B. H. Update on lupus nephritis. Clin. J. Am. Soc. Nephrol. CJASN 12, 825–835. https://doi. org/10.2215/cjn.05780616 (2017).
2. Mok, C. C., Kwok, R. C. & Yip, P. S. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 65, 2154–2160. https://doi.org/10.1002/art.38006 (2013).
3. Danila, M. I. et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford, England) 48, 542–545. https://doi.org/10.1093/rheumatology/kep012 (2009).
4. Austin, H. A. 3rd., Boumpas, D. T., Vaughan, E. M. & Balow, J. E. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 45, 544–550. https://doi.org/10.1038/ki.1994.70 (1994).
5. Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I. & Estes, D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am. J. Med. 83, 877–885. https://doi.org/10.1016/0002-9343(87)90645-0 (1987).
6. Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934–3940. https://doi.org/10.1002/ art.20666 (2004).
7. Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M. & Lewis, E. J. Value of a complete or partial remission in severe lupus nephritis. Clin. J. Am. Soc. Nephrol. CJASN 3, 46–53. https://doi.org/10.2215/cjn.03280807 (2008).
8. Hanaoka, H., Iida, H., Kiyokawa, T., Takakuwa, Y. & Kawahata, K. Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res. Ther. 20, 86. https://doi.org/10.1186/s13075-018-1576-1 (2018).
9. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65, 521–530. https://doi.org/10.1111/j.1523-1755.2004.00443.x (2004).
10. Yokoyama, H. et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int. 66, 2382–2388. https://doi.org/10.1111/j.1523-1755.2004.66027.x (2004).
11. Sada, K. E. & Makino, H. Usefulness of ISN/RPS classification of lupus nephritis. J. Korean Med. Sci. 24(Suppl), S7-10. https://doi. org/10.3346/jkms.2009.24.S1.S7 (2009).
12. Chow, T. K., Looi, L. M. & Cheah, P. L. A comparison of 1995 WHO classification with 2003 ISN/RPS classification of lupus nephritis: a single centre observation. Malays. J. Pathol. 37, 239–246 (2015).
13. Hiramatsu, N. et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford, England) 47, 702–707. https://doi.org/10.1093/rheum atology/ken019 (2008).
14. Furness, P. N. & Taub, N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am. J. Surg. Pathol. 30, 1030–1035. https://doi.org/10.1097/00000478-200608000-00015 (2006).
15. Wilhelmus, S. et al. The revisited classification of GN in SLE at 10 years: time to re-evaluate histopathologic lesions. J. Am. Soc. Nephrol. JASN 26, 2938–2946. https://doi.org/10.1681/asn.2015040384 (2015).
16. Grootscholten, C. et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephri- tis. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Renal Assoc. 23, 223–230. https://doi.org/10.1093/ndt/gfm555 (2008).
17. Wilhelmus, S. et al. Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin. J. Am. Soc. Nephrol. CJASN 10, 47–53. https://doi.org/10.2215/cjn.03580414 (2015).
18. Wu, L. H. et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 83, 715–723. https://doi.org/10.1038/ki.2012.409 (2013).
19. Obrisca, B. et al. Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scor- ing of glomerular lesions. Lupus 27, 1455–1463. https://doi.org/10.1177/0961203318776109 (2018).
20. Wilson, P. C., Kashgarian, M. & Moeckel, G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin. Kidney J. 11, 207–218. https://doi.org/10.1093/ckj/sfx093 (2018).
21. Yu, F. et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int. 77, 820–829. https://doi.org/10.1038/ki.2010.13 (2010).
22. Hsieh, C. et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res. 63, 865–874. https://doi.org/10.1002/acr.20441 (2011).
23. Rijnink, E. C. et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin. J. Am. Soc. Nephrol. CJASN 12, 734–743. https://doi.org/10.2215/cjn.10601016 (2017).
24. Bajema, I. M. et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 93, 789–796. https://doi.org/10.1016/j.kint.2017.11.023 (2018).
25. Austin, H. A. 3rd. et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am. J. Med. 75, 382–391. https://doi.org/10.1016/0002-9343(83)90338-8 (1983).
26. Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythe- matosus. Arthritis Rheum. 40, 1725. https://doi.org/10.1002/art.1780400928 (1997).
27. Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kid. Dis. Off. J. Natl. Kidney Found. 53, 982–992. https://doi.org/10.1053/j.ajkd.2008.12.034 (2009).
28. Romero-Diaz, J., Isenberg, D. & Ramsey-Goldman, R. Measures of adult systemic lupus erythematosus: updated version of Brit- ish Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res. 63(Suppl 11), S37-46. https://doi.org/10.1002/acr.20572 (2011).
29. Austin, H. A. 3rd., Boumpas, D. T., Vaughan, E. M. & Balow, J. E. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Renal Assoc. 10, 1620–1628 (1995).
30. Austin, H. A. 3rd., Muenz, L. R., Joyce, K. M., Antonovych, T. T. & Balow, J. E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25, 689–695. https://doi.org/10.1038/ki.1984.75 (1984).
31. Cattran, D. C. et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534–545. https://doi.org/10.1038/ki.2009.243 (2009).
32. Radhakrishnan, J. & Cattran, D. C. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–appli- cation to the individual patient. Kidney Int. 82, 840–856. https://doi.org/10.1038/ki.2012.280 (2012).
33. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. JASN 20, 1103–1112. https://doi.org/10.1681/asn.2008101028 (2009).